This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
1 Lung Cancer Statistics.- 2 Epidemiology of Lung Cancer.- 3 Lung Cancer In Never Smokers.- 4 Immune Therapy.- 5 Anti-angiogenesis in personalized therapy of lung cancer.- 6 Target therapy in Lung Cancer.- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update.- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.- 10 Chemotherapy Resistance in Lung Cancer.- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
“The aim of this book is to discuss current knowledge about lung cancer with a specific focus on non-small-cell lung cancer (NSCLC). … The intended audience is established researchers, clinicians, healthcare professionals, and students in the medical and scientific community. … The authors have successfully compiled a well-written, comprehensive, and robust book about NSCLC … .” (Karen L. Reckamp, Doody’s Book Reviews, August, 2016)
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
Succintly combines the most current research on lung cancer from epidemiology to recent breakthroughs in personalized therapies
